By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.

Close

Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Close

MHRA extend swine flu adverse drug reaction portal

The MHRA have extended the swine flu adverse drug reaction (ADR) portal to include swine flu vaccines and seasonal vaccines.

In July 2009 the MHRA launched a special swine flu ADR portal for reporting suspected adverse drug reaction to oseltamivir (Tamiflu) and zanamivir (Relenza).

The MHRA now have extended use of this portal to include suspected ADRs to new swine flu vaccines and seasonal vaccines.

Reports should include;

  • the patient’s age;
  • a description of the suspected adverse reaction and outcome;
  • any underlying risk factors.

Click here for further information.

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!

newsletterpromo